| 作成者 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| 本文言語 |
|
| 出版者 |
|
|
|
| 発行日 |
|
| 収録物名 |
|
|
|
| 巻 |
|
| 号 |
|
| 開始ページ |
|
| 会議情報 |
|
| 出版タイプ |
|
| アクセス権 |
|
| 概要 |
Metastasis-associated proteins, such as S100A4 and MTA1, have been studied for over two decades, but correlation between them is not understood. A recent report suggesting that silencing of S100A4 in ...endothelial cells suppresses in vitro tube formation and in vivo tumor angiogenesis, motivated us to examine MTA1 from the same perspective. In this study, we showed that the suppression of MTA1 in endothelial cells by murine MTA1 siRNA (mMTA1 siRNA) inhibited tube formation in vitro. We found that mMTA1 siRNA has an anti-angiogenic activity in vivo targeting endothelial cells using directed in vivo angiogenesis assay (DIVAA). Moreover, we found mMTA1 siRNA inhibited tumor angiogenesis in a xenograft model. Further, we revealed that inhibition of angiogenesis by mMTA1 siRNA mediates downregulation of S100A4 followed by promoting phosphorylation of non-muscle myosin IIA (NMIIA). These data suggested that silencing of MTA1 in endothelial cells could be used as a new strategy to regress tumors, by inhibiting tumor angiogenesis.続きを見る
|
Mendeley出力
